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Abstract Human epididymis protein 4 (HE4), represented as
an epididymis-specific gene and designated a WAP four-
disulfide core domain protein 2 (WFDC2), is amplified in
many tumors. However, little is known about its clinical
significance and biological function in gastric carcinomas.
We found that HE4 was more commonly observed in gastric
carcinoma tissues than in normal tissues and was significantly
correlated with Lauren classification, TNM stage, and tumor
size by immunohistochemistry. The overall survival rate of
patients with HE4 low expression was significantly higher
than that of the patients with HE4 high expression. In addition,
silencing of HE4 expression inhibits cell proliferation and
migration and enhances cell apoptosis. Subsequent studies
reveal that the Src, Akt, and Erk1/2 signaling may be involved
with pro-survival and anti-apoptotic effects of the HE4 on
gastric cancer cells. Taken together, this study provides new
evidence on promotive effects of the HE4 on gastric cancer
progression and indicates that HE4 might be a promising
prognostic factor for gastric cancer diagnosis.
Keywords HE4 . Gastric cancer . Apoptosis . Proliferation .
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Introduction
Globally, gastric cancer is one of the most common malignan-
cies [1] and the leading cause of cancer-related death in China
[2]. Despite the trend for decreasing incidence, the 5-year
survival rate of gastric carcinoma is approximately 27 % for
patients from 2001 to 2007 [3]. Additionally, some chemo-
therapeutic drugs have no ideal curative effects and further-
more have many unexpected side effects. Therefore, it is
essential to further explore the molecular mechanisms of
development and progression of gastric carcinoma and expect
specific and sensitive markers with valuable and early
diagnosis.
Human epididymis protein 4 (HE4) was found as a marker
of cancer recently and has been reported in multiple types of
neoplasia [4, 5] such as ovarian cancer [5], endometrial cancer
[1], lung cancer [6], and breast cancer [7], whereas there are
no reports about HE4 on clinicopathological significance,
cellular function, and mechanism in gastric carcinoma.
In our study, we ascertained that the HE4 was significantly
upregulated in human gastric cancer and correlated with
Lauren classification, TNM stage, and tumor size, and the
overall survival rate of patients without HE4 expression was
significantly higher than the rate of those with HE4 overex-
pression. In addition, we characterized that silencing the HE4
inhibited proliferation and migration and enhanced apoptosis.
Furthermore, we found that the HE4 might regulate prolifer-
ation, migration, and apoptosis through Src/Fak, Akt, and
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Erk1/2 signaling in gastric cancer cells. In conclusion, our
findings illuminate that HE4 might be a new therapeutic value
marker for gastric cancer.
Materials and methods
Cell culture
The human gastric cancer cell lines (MKN-28, MKN-45,
MGC-803, NCI-N87, and HGC-27) were obtained from the
American Type Culture Collection. All cell lines were grown
at 37 °C in 5 % CO2 in RPMI 1640 medium (Gibco) or
Dulbecco’s modified Eagle’s medium (Gibco) with 10 % fetal
bovine serum (Gibco).
Patients’ samples
A total of 250 gastric carcinomas were consecutively collected
from surgical resection at Shanghai Cancer Center between 1
January 2005 and 31 December 2008. None of the patients
with carcinomas (31–86 years, mean=62 years) underwent
either chemotherapy or radiotherapy before surgery. All tumor
tissue specimens were obtained with informed consent for
clinical research, and protocols were approved by the ethical
review committee of the World Health Organization
Collaborating Center for Research in Human Production (au-
thorized by the Shanghai Municipal Government). All pa-
tients were followed up by consulting their documents and
through telephone interviews.
Quantitative reverse transcriptase-PCR
According to the manufacturer’s instruction, total RNA was
abstract by TRIzol reagent (Invitrogen). Complementary
DNA was synthesized using Prime Script RT Reagent Kit
(TaKaRa). The expression of HE4 was evaluated by quantita-
tive reverse transcriptase-PCR (q-PCR) in anABI7500 system
using SYBR Green PCRMaster Mix Reagents Kit (TaKaRa).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control.
siRNA interference
Three synthetic double-stranded siRNAs, which target the
HE4, were transfected into MKN-28 cells and MGC-803
cells, respectively, with RNAi Mate Transfection Agent
(GenePharma) for 48 h. The cells were considered as cells
transient knockdown HE4 and verified by quantitative real-
time PCR and Western blotting analysis.
Western blot analysis
Cell protein lysates were denatured by boiling for 5 min and
separated by 4–12 % SDS-PAGE and transferred to nitrocel-
lulose membranes. After blocking with 5 % skimmed milk for
1 h at room temperature, membranes were then incubated with
primary antibodies: anti-HE4 (Abcam), anti-p-AKT, anti-
AKT, anti-p-Erk, anti-Erk, anti-p-FAK, anti-FAK, anti-p-Src
and anti-Src (Cell signaling), and GAPDH (Sigma) overnight
at 4 °C. Horseradish peroxidase-labeled goat anti-rabbit
(1:1000) or goat anti-mouse (1:5000) IgG (Proteintech) was
incubated for 1 h at room temperature. Specific protein bands
were developed using the Odyssey imaging system (LI-COR).
Tissue microarrays
Core tissue biopsy specimens (diameter 2 mm) were obtained
from individual paraffin-embedded gastric carcinomas (donor
blocks) and arranged in new recipient paraffin blocks (tissue
assay blocks). Nonneoplastic gastric mucosa specimens were
included in each of the assay blocks.
Immunohistochemistry
Gastric carcinoma tissue arrays were first incubated using the
antibody for HE4. The sections were immunostained with
primary anti-HE4 (1:50 Abcam) and a universal biotinylated
secondary antibody was developed. Scoring was conducted
according to the ratio and intensity of positive-staining cells:
0–10 % scored 0, 11–30 % scored 1, 31–60 % scored 2, and
61–100 % scored 3. Then scored 0–1 was designated as low
expression and scored 2–3 as high expression.
Migration assay
Cells were seeded in triplicate in 24-well Transwell plates
(Coster) for 24 h. Then, the migratory cells on the lower
surface were fixed with methanol and stained with hematox-
ylin. For quantification, cells were counted under a micro-
scope in five predetermined fields.
Proliferation assay
Cells were seeded in 96-well plates at 3×103 cells per well.
Five independent experiments were performed in triplicate.
According to the manufacturer’s protocol, Cell Counting Kit-
8 (CCK8, Dojindo, Japan) was used to measure cell viability
for 4 days. And cell viability was obtained by measuring the
absorbance at 450 nm wavelength using Power Wave XS
microplate reader (BIO-TEK).
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Flow cytometry
Apoptotic cells were analyzed using Annexin V-FITC and PI
(BD Biosciences Clontech). Cells were trypsinized, washed
twice with 4 °C PBS, and then resuspended in 1× binding
buffer at 1×106 cells/ml. Each of the cells were washed with
1× PBS and stained with 200 μl binding buffer containing
3.5 μl Annexin Vand 3.5 μl propidium iodide (PI), incubated
at room temperature for 20 min, and analyzed using flow
cytometry (BD Biosciences Clontech).
Statistical analysis
The SPSS 16.0 program (SPSS, Chicago, IL, USA) was used
for statistic analysis. Kaplan-Meier survival plots were gener-
ated, and comparisons between the survival curves were made
with the log-rank test. The chi-square test and Student’s t test
were used for comparison between groups. All data were
shown as mean±SD. P<0.05 was considered statistically
significant.
Results
HE4 is frequently upregulated in gastric cancer tissues
To study the discrepancies of HE4 in gastric carcinoma, we
detected the expressions of HE4 on the gastric cancer tissue
array using immunohistochemical analysis. In 243 cases of
normal gastric mucosa, weak nuclear staining was identified
in only 11 cases for HE4 with 4.53 % (11/243). However,
strong expression of HE4 was identified in 62.96 % (153/243)
of gastric carcinoma patients. There was statistical signifi-
cance between the expressions of HE4 in normal gastric
mucosa (Fig. 1a) and gastric carcinoma (Fig. 1b–d).
Collectively, these findings suggest that HE4 is upregulated
in gastric cancer tissues.
HE4 expression is closely related to Lauren classification,
TNM stage, tumor size, and patient prognosis in gastric cancer
In 243 cases of gastric carcinoma, the HE4 expression was not
significantly related to patient age, gender, Japanese classifi-
cation, tumor stage, lymph node metastasis and tumor inva-
sion (P>0.05). Nevertheless, the expression of HE4 was
significantly correlated with Lauren classification (P=
0.043), TNM stage (P=0.020), and tumor size (P=0.042)
(Table 1).
Next, we observed that the mean duration of follow-up was
47 months after surgery and 75th percentile of duration was
55 months. During the follow-up period, 97 of the 243 pa-
tients (39.9 %) died. The overall survival rate of patients with
HE4 overexpression, as determined by the log-rank test, was
significantly lower than the rate of those without HE4 expres-
sion (P=0.045) (Fig. 2).
Silencing of HE4 expression enhances apoptosis and inhibits
proliferation
Emerging evidences have shown that HE4 is upregulated in
ovarian, endometrial, lung, and breast cancer, etc. [1, 5–7]; we
Fig. 1 HE4 is frequently
upregulated in gastric cancer
tissues. Representative
photomicrographs of the HE4
immunoreactivity in normal
gastric mucosa (a), poorly
differentiated adenocarcinoma
(b), moderately differentiated
adenocarcinoma (c), and well-
differentiated adenocarcinoma
(d). The arrows represent HE4
positive staining without reaction
in the nuclei (scale bar: 50 μm)
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thus examined the mRNA level of HE4 in gastric cancer cells
by quantitative real-time PCR. Our data identified that HE4
was upregulated in a panel of gastric cancer cell lines (MKN-
28, MKN-45, MGC-803, NCI-N87, and HGC-27) (Fig. 3a).
To determined whether HE4 protein are responsible for
gastric cancer progression, we used three different small in-
terfering RNAs to interfere HE4 in gastric cancer cells MKN-
28 and MGC-803, which are higher in the mRNA level of
HE4. Then, we examined the mRNA level of the siRNAs in
MKN-28 and MGC-803, respectively. We found that the
mRNA level of siRNA1, siRNA2, and siRNA3 was 14.3,
22.2, and 66.8 % in gastric cancer cell MKN-28 (Fig. 3b),
while the mRNA level of siRNA1, siRNA2, and siRNA3 was
Table 1 Statistic analysis of HE4 with patients’ clinicopathologic parameters
Characteristics HE4 expression level χ2 P value
Negative Low Middle High
Age (years) <65 51 47 22 16 0.921 0.820
≥65 39 41 18 9
Sex Female 67 58 28 16 1.936 0.586
Male 23 30 12 9
Lauren’s classification Intestinal 39 21 15 7 8.163 0.043
Diffuse 51 67 25 18
Histologic grade Pap 1 2 1 1 12.774 0.805
Tub1 3 2 1 0
Tub2 32 30 18 8
Por1 46 42 16 14
Por2 0 1 0 0
Muc 2 2 3 2
Sig 4 7 1 0
Depth of invasion T1 20 12 4 2 10.356 0.322
T2 12 15 8 2
T3 51 48 21 18
T4 7 13 7 3
TNM stage I 26 19 7 3 19.671 0.020
II 23 29 12 4
III 33 36 19 11
IV 8 4 2 7
Lymph node metastasis Positive 47 44 23 17 2.850 0.415
Negative 43 44 17 8
Lymph Yes 13 5 8 2 6.822 0.078
No 77 83 32 23
Tumor size <4 cm 46 34 13 6 8.198 0.042
≥4 cm 44 54 27 19
Differentiation Well 9 10 3 2 7.828 0.251
Moderate 27 26 21 8
Poor 54 52 16 15
Pap papillary adenocarcinoma, Tub1 well-differentiated tubular adenocarcinoma, Tub2 moderately differentiated tubular adenocarcinoma, Por1 solid
poorly differentiated adenocarcinoma, Por2 non-solid poorly differentiated adenocarcinoma, Muc mucinous adenocarcinoma, Sig signet-ring cell
carcinoma
Fig. 2 The relationship between expression of HE4 protein and patients’
prognosis. The overall survival rate of patients with HE4 low expression,
as determined by the log-rank test, was significantly higher than the rate
of those with HE4 high expression (P=0.045)
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37.6, 24.7, and 44.2 % in gastric cancer cell MGC-803
(Fig. 3c). Similarly, the expression pattern of siRNAs in
gastric cancer cells MKN-28 and MGC-803 consisted with
the mRNA level (Fig. 3b, c). All the data indicated that
siRNA1 and siRNA2 could notably restrain HE4, which were
considered statistically significant. Therefore, siRNA1 and
siRNA2 were chosen for the follow-up tests.
In MKN-28 and MGC-803 cells treated with a HE4-
specific siRNA1 and siRNA2, the number of early and late
apoptotic cells was significantly higher than control group,
Fig. 3 The expression level of
HE4 in different gastric cancer
cells lines and validation of
siRNA interference efficiency. a
MKN-28 and MGC-803 are
higher than other gastric cancer
cells in the mRNA level of HE4.
The siRNA1 and siRNA2 could
notably restrain HE4 by real-time
PCR (b) and Western blotting (c)
in MKN-28 cells. The siRNA1
and siRNA2 could notably
restrain HE4 by real-time PCR (d)
and Western blotting (e) in MGC-
803 cells. (sh-NC versus sh-1 or
sh-2, *P<0.05; **P<0.01)
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after the cells were starved for 24 h. We conclude that the
deficient HE4 expression level promotes apoptosis in gastric
cancer cells (Fig. 4a, b).
Because HE4 expression was significantly correlated with
tumor size mentioned above, we first measured the cell via-
bility using CCK8 reagent and found that suppressive effect
on the cell growth was not an immediate cell response in
MKN-28 and MGC-803 cells treated with a HE4-specific
siRNA1 and siRNA2; rather, it tookmore than 24 h to become
prominent (Fig. 4c, d). We infer from these results that gastric
cancer cells with low HE4 expression levels have a growth
disadvantage.
Silencing of HE4 expression inhibits migration
Next, to investigate the effects of downregulating HE4 on
migration, we conducted in vitro migration assays to evaluate
the migration ability of MKN-28 and MGC-803 cells. MKN-
28 cells treated with a HE4-specific siRNA1 and siRNA2
decreased averagely in migration of 56.7 % (144.0±15.0 cells
versus 253.8±15.6 cells per field, respectively; P<0.05) and
50.0 % compared to the control cells (127.1±5.9 cells versus
253.8±15.6 cells per field, respectively; P<0.05) (Fig. 5a).
Furthermore, MGC-803 cells treated with a HE4-specific
siRNA1 and siRNA2 decreased averagely in migration of
48.6 % (79.7±7.4 cells versus 164.0±14.6 cells per field,
respectively; P<0.05) and 38.5 % compared to the control
cells (164.0±14.6 cells versus 63.2±10.6 cells per field, re-
spectively; P<0.05) (Fig. 5b). These results suggest that HE4
expression is associated with the migration potential of gastric
cell lines in vitro.
Silencing of HE4 affects Src, Akt, and Erk1/2 signaling
in gastric cancer cells
We were interested in how HE4 regulates proliferation, mi-
gration, and apoptosis; hence, we further explored the intra-
cellular signaling. The results showed that silencing HE4
could significantly diminish the phosphorylation level of
Akt, Erk1/2, Fak, and Src which play important roles in
regulating cell proliferation, migration, and apoptosis [16].
The data facilitates that the identification of HE4 regulates
proliferation, migration, and apoptosis through Src/Fak, Akt,
and Erk1/2 signaling in gastric cancer cells (Fig. 6a–e).
Discussion
Gastric cancer is the fourth most common carcinomas world-
wide; however, its incidence and mortality varies geographi-
cally [8]. In China, the mortality rate of gastric cancer ranked
the third in overall cancer mortality [9].
The HE4 (WFDC2) encodes a protein which has a WAP-
type four-disulfide core domain [10] and was initially found in
the distal epididymis epithelium [5, 11]. Hellstrom et al. re-
ported that the quantitation of the HE4 protein levels in serum
was more frequently positive than that of the CA125 levels in
ovarian cancer; therefore, it could be used as a biomarker of
ovarian cancer [5]. And their subsequent study confirmed the
observation [12]. Likewise, study from Moore et al. showed
that the HE4 was elevated at all stage of the endometrial
cancer by examining the levels of the HE4 in the pre-
operative serum samples from surgically staged patients with
Fig. 4 Silencing of HE4
enhances apoptosis and inhibits
proliferation in gastric cancer
cells. Apoptosis ratio of MKN-28
(a) and MGC-803 (b) cells were
analyzed by Annexin Vand PI
staining and flow cytometric
analysis (sh-NC versus sh-1 or sh-
2, *P<0.05; **P<0.01). Statistic
data shown right are means±SD
of apoptotic cell rates from
triplicate samples. Data are
representative of three
independent experiments. Effect
of HE4 knockdown on cell
survival of MKN-28 (c) and
MGC-803 (d) cells with serum
deprivation were analyzed by
CCK8 assay (sh-NC versus sh-1
and sh-NC versus sh-2, *P<0.05;
**P<0.01)
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endometrioid adenocarcinoma of the uterus [13]. Recently, the
HE4 has been found to be differently expressed in various
cancers such as ovarian cancer [5], endometrial cancer [1],
lung cancer [6], breast cancer [7], etc.
Fig. 6 a–e Silencing of HE4
inhibits activation of ERK1/2 and
AKT. Analysis of activation of
Akt, Erk1/2, Fak, Src in HE4
knockdown MKN-28, and MGC-
803 cells using GAPDH as a
loading control
Fig. 5 Silencing of HE4 inhibits gastric cancer cells migration. MKN-28
cells (a, b) and MGC-803 (c, d) cells that migrated through the transwell
chambers and photographed at ×100 magnification. The in vitro
migration ability of MKN-28 cells (a, b) and MGC-803 (c, d) was
measured by determining the number of uncoated cells that penetrated
through the transwell chambers (columnsmean values, bar SD; *P<0.05;
**P<0.01)
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Kristjansdottir et al. used a cohort of 373 patient
blood samples from women scheduled for surgery for
a malignant suspicious cystic ovarian mass and showed
the significant variations of HE4 and CA125 levels
within different tumors and histotypes, and the highest
levels of HE4 and CA125 were in the more aggressive
and genetically highly instable tumors [14]. In accor-
dance with our study, we discovered that the HE4
expression was significantly correlated with Lauren clas-
sification (P=0.043), TNM stage (P=0.020), and tumor
size (P=0.042) (Table 1). Furthermore, we found that
the overall survival rate of the patients without the HE4
expression was significantly higher than the rate of
those with the HE4 overexpression. These results were
in line with the previous studies that the 5-year overall
survival rate was lower in the HE4-positive group than
that in the HE4-negative group in pulmonary adenocar-
cinoma [15].
To further explore the molecular mechanisms of the
development and progression of gastric carcinoma, we
explored the functions of the HE4 in the gastric cancer
cell lines and tissues. As expected, we found that the
repression of the HE4 expression inhibited proliferation
and migration and enhanced apoptosis. Collectively, the-
se observations indicated that the HE4 might play an
important regulatory role in the development and pro-
gression of gastric carcinoma.
Moreover, recent studies have shown that the levels
of phosphorylated Akt and ERK1/2 regulate various cell
functions, such as angiogenesis, immigration, and sur-
vival [16]. Therefore, we explored the intracellular sig-
naling and found that silencing the HE4 could signifi-
cantly diminish the phosphorylation level of Akt,
Erk1/2, Fak, and Src. These results facilitate the identi-
fication of the HE4 regulating proliferation, migration,
and apoptosis through Src/Fak, Akt, and Erk1/2 signal-
ing in gastric cancer cells.
In conclusion, the HE4 in our study of the gastric
cancer is applicable for histopathologic diagnosis and
might be a new target for therapeutic interventions.
We will amplify samples of sera from patients with
gastric cancer to verify our observation and explore
the intracellular signaling in further study.
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